Immediate Access to Vital Information

• Strategies for accessing outpatient and inpatient drug discounts and maximizing savings under the 340B program
• Five (5) free telephone consultations per year on 340B troubleshooting and implementation issues
• Free subscriptions to SNHPA’s Member Bulletin and the Drug Discount Monitor, the definitive sources for the latest 340B news
• Regular webinars, regional roundtables, and other educational opportunities
• Actions by Congress and federal agencies affecting the 340B drug discount program
• Regular updates on drug pricing and compliance matters
• Guidance on inventory management/split billing
• Drug pricing clearinghouse comparing 340B pricing files and identifying best buys
• Interactive Web site with key drug pricing documents and instant access to members through listserv
• Advice on which patients and institutions qualify for 340B
• A Survival Kit to help ensure compliance with 340B law and maximize discounts
• Resources to reduce the administrative burden of drug manufacturer patient assistance programs
• Discounts on advertising in Rx Job Solutions (www.rxjobsolutions.org), your source to readily find qualified 340B and safety net pharmacy experts

Legislative/Regulatory Advocacy

• Protect 340B from legislative efforts to narrow its scope or repeal the program
• Engage Congress in extending 340B discounts to the inpatient setting
• Protect 340B providers from Medicare and Medicaid reimbursement cuts
• Work with Congress, federal agencies and private sector on Medicare Parts B and D
• Help member hospitals collect retroactive rebates on drug overpayments
• Advocate for reasonable patient definition and inventory management standards
• Work with the Office of Pharmacy Affairs and the Prime Vendor Program
• Collaborate with PSSC on educational forums and technical assistance matters
• Participate in Congressional lobbying days in Washington, DC
• Educate and assist members with developing contract pharmacy arrangements and pharmacy networks

Member Input and Networking

• Conferences and webinars with speakers from 340B hospitals, federal agencies, Congress and the pharmaceutical industry
• Member-only meetings throughout the country, and regional roundtables to share 340B strategies and best practices
• Web site that enables instant communication with other members on strategies to reduce drug costs and other troubleshooting issues
• Committee participation:  Board of Directors, Government Relations, Patient Assistance Programs, Medicare Part D, Membership and other advisory committees

Dialogue with Pharmaceutical Industry

• Access to 340B contract specialists at pharmaceutical companies, wholesalers and Prime Vendor Program
• Sample letters to contact industry or government on potential 340B overpayments
• Advice on audit procedures and dispute resolution
• Work with industry on patient assistance programs, Medicare drug benefit, inpatient discounts and drug shortages
• Roundtable meetings with manufacturers, wholesalers and government on troubleshooting issues

All of the benefits listed above plus:

• Specialized webcasts and conference calls on key policy, operational and compliance issues. These presentations are designed to educate pharmacy department representatives, senior management and other interested parties within participating hospitals on the full range of 340B issues relevant to your hospital.
• Additional one-on-one technical assistance troubleshooting calls with SNHPA staff and counsel. Members who choose the enhanced member level will be able to participate in 10 calls per year (compared to the five that are included in the Standard Level membership).
• Price verification services.  While SNHPA will assist all members with questions over 340B pricing matters, enhanced level members will have access to SNHPA’s pricing experts who will help guide members on potential overcharges and recovery.
• Special recognition on SNHPA’s Web site of your hospital’s increased level of commitment to achieving SNHPA’s advocacy goals, especially protection of the 340B program from unreasonable restrictions and extension of 340B discounts to inpatient drugs.